Antitrust concerns and the FDA approval process : hearing before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Committee on the Judiciary, House of Representatives, One Hundred Fifteenth Congress, first session, July 27, 2017.

Bibliographic Details
Corporate Author:	United States. Congress. House. Committee on the Judiciary. Subcommittee on Regulatory Reform, Commercial and Antitrust Law (Author)
Language:	English
Published:	Washington : U.S. Government Publishing Office, 2018.
Subjects:	United States. > Food and Drug Administration > Rules and practice. Drugs > United States > Testing. Drug approval > United States. Drugs > Safety regulations > United States. Medical instruments and apparatus > Safety regulations > United States. Generic drugs > United States. Competition > United States. Antitrust law > United States. United States. > Food and Drug Administration. Antitrust law. Competition. Drug approval. Drugs > Safety regulations. Drugs > Testing. Generic drugs. Medical instruments and apparatus > Safety regulations. United States.
Genre:	Rules and practice.
Online Access:	Connect to online resource - All users (Federal Depository Library Program Persistant URL)
Physical Description:	1 online resource (iv, 51 pages)
Variant Title:	Antitrust concerns and the Food and Drug Administration approval process
Format:	Government Document Electronic eBook

Similar Items

FDA's drug review process and the package label strategies for writing successful FDA submissions
by: Brody, Tom, et al.
Published: (2018)

Access to unapproved drugs : FDA policies on compassionate use and emergency use authorization
by: Thaul, Susan
Published: (2018)

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act : report (to accompany H.R 2374) (Including cost estimate of the Congressional Budget Office).
Published: (2020)

Examining concerns regarding FDA's proposed changes to generic drug labeling : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 1, 2014.
Published: (2016)

Drug pricing and the law : regulatory exclusivities
by: Ward, Erin H.
Published: (2019)

Rx for generic drug safety : accurate information for older Americans : hearing before the Subcommittee on Housing and Consumer Interests of the Select Committee on Aging, House of Representatives, One Hundred First Congress, second session, March 1, 1990.
Published: (1990)

Rx for generic drug safety : accurate information for older Americans : hearing before the Subcommittee on Housing and Consumer Interests of the Select Committee on Aging, House of Representatives, One Hundred First Congress, second session, March 1, 1990.
Published: (1990)

Guidance for industry : alternate source of the active pharmaceutical ingredient in pending ANDAs.
Published: (2000)

The administration's FDA reforms and reduced biopharmaceutical drug prices
Published: (2018)

FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session.
Published: (1989)

FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session.
Published: (1989)

Biosimilarity : the FDA perspective
by: Niazi, Sarfaraz, 1949-
Published: (2019)

FDA-approved bargain drugs : generic products must meet high standards.
Published: (2003)

Examining concerns regarding FDA's proposed changes to generic drug labeling : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 1, 2014.
Published: (2016)

FDA's approach to reviewing over-the-counter drugs is reasonable, but progress is slow : report to the Congress
Published: (1982)

FDA fast track and priority review programs
by: Thaul, Susan
Published: (2018)

Generic drug user fee amendments : accelerating patient access to generic drugs : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session ... January 28, 2016.
Published: (2018)

FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session.
Published: (1989)

Building a 21st century FDA : proposals to improve drug safety and innovation : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, second session, on examining proposals to improve drug safety and innovation, and S. 3807, to amend the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act to improve drug safety and oversight, November 16, 2006.
Published: (2007)

Building a 21st century FDA proposals to improve drug safety and innovation : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, second session, on examining proposals to improve drug safety and innovation, and S. 3807, to amend the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act to improve drug safety and oversight, November 16, 2006.
Published: (2007)

Drugs and the FDA safety, efficacy, and the public's trust
by: Sekeres, Mikkael A.
Published: (2022)

Preparing for FDA pre-approval inspections
Published: (1999)

New drug approval : FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints : report to the Ranking Member, Committee on Finance, U.S. Senate.
Published: (2009)

FDA's generic drug application policy : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, second session, July 28, 1988.
Published: (1989)

FDA's generic drug application policy : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, second session, July 28, 1988.
Published: (1989)

FDA's generic drug application policy : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, second session, July 28, 1988.
Published: (1989)

FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session.
Published: (1989)

FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session.
Published: (1989)

Frecuentes preguntas acerca de las drogas genéricas.
Published: (2004)

Council on Competitiveness and FDA plans to alter the drug approval process at FDA hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, second session, March 19, 1992.
Published: (1993)

Restoring FDA's ability to keep America's families safe : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, second session ... April 24, 2008.
Published: (2009)

FDA's review process for new drug applications : a management review.
Published: (2003)

Greater access to generic drugs
by: Meadows, Michelle
Published: (2004)

Restoring FDA's ability to keep America's families safe : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, second session, on examining the U.S. Food and Drug Administration, focusing on its ability to ensure the safety of food and the drug supply in the United States, April 24, 2008.
Published: (2009)

Restoring FDA's ability to keep America's families safe hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, second session, on examining the U.S. Food and Drug Administration, focusing on its ability to ensure the safety of food and the drug supply in the United States, April 24, 2008.
Published: (2009)

Revitalizing new product development from clinical trials through FDA review hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Fourth Congress, second session, on S. 1477 ... February 21, 1996.
Published: (1996)

Las drogas baratas aprobadas por la FDA : los productos genéricos deben satisfacer altos niveles.
Published: (2004)

FDA's generic drug enforcement and approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, March 7 and June 5, 1991.
Published: (1992)

Inside the FDA : the business and politics behind the drugs we take and the food we eat
by: Hawthorne, Fran
Published: (2005)